ERBB2 and breast cancer: To improve the predictive performance of the model, we integrated the US and clinicopathological characteristics to construct a regression model with an AUC of 0.808 for the combined model, which further demonstrated the great clinical application of the combined model we constructed in predicting the early outcome of NACT in HER2-positive breast cancer patients.